AXSM | Axsome Therapeutics, Inc.

Index- P/E- EPS (ttm)-3.80 Insider Own18.49% Shs Outstand43.52M Perf Week-0.51%
Market Cap3.15B Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float35.41M Perf Month-8.08%
Income-158.70M PEG- EPS next Q-1.27 Inst Own60.40% Short Float / Ratio21.66% / 9.74 Perf Quarter26.29%
Sales144.60M P/S21.81 EPS this Y-32.80% Inst Trans18.62% Short Interest7.67M Perf Half Y-5.66%
Book/sh2.57 P/B28.69 EPS next Y61.10% ROA-51.20% Target Price111.92 Perf Year166.50%
Cash/sh5.76 P/C12.79 EPS next 5Y- ROE-161.20% 52W Range20.63 - 82.85 Perf YTD-4.40%
Dividend- P/FCF- EPS past 5Y-29.30% ROI-88.20% 52W High-11.00% Beta1.91
Dividend %- Quick Ratio2.90 Sales past 5Y- Gross Margin91.20% 52W Low257.44% ATR2.90
Employees383 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)51.42 Volatility3.19% 3.86%
OptionableYes Debt/Eq1.32 EPS Q/Q75.10% Profit Margin- Rel Volume0.54 Prev Close75.24
ShortableYes LT Debt/Eq1.32 EarningsMay 08 BMO Payout- Avg Volume787.44K Price73.74
Recom1.90 SMA20-0.79% SMA504.07% SMA20014.91% Volume421,868 Change-1.99%
Date Action Analyst Rating Change Price Target Change
Jan-05-23Initiated Piper Sandler Neutral $75
Nov-01-22Initiated Loop Capital Buy $95
Sep-07-22Resumed Mizuho Buy $49 → $76
Aug-10-21Downgrade Morgan Stanley Overweight → Equal-Weight $105 → $34
Jun-10-21Initiated Berenberg Buy $112
Jan-08-21Initiated Jefferies Buy $129
Dec-16-20Initiated Mizuho Buy $120
Sep-29-20Initiated BofA Securities Underperform $66
Sep-10-20Initiated Morgan Stanley Overweight $102
Apr-28-20Reiterated H.C. Wainwright Buy $200 → $210
Jun-09-23 02:00PM
Jun-01-23 07:00AM
May-30-23 07:00AM
May-28-23 10:15AM
May-26-23 09:37AM
07:45AM Loading…
May-22-23 07:45AM
May-20-23 09:30AM
May-17-23 05:30AM
May-13-23 08:13AM
May-10-23 05:11AM
May-09-23 03:37PM
May-08-23 11:12PM
02:00PM Loading…
May-04-23 01:56PM
May-03-23 07:00AM
May-01-23 07:00AM
Apr-28-23 06:26AM
Apr-25-23 06:00AM
Apr-23-23 05:30AM
Apr-22-23 06:18AM
Apr-21-23 07:00AM
Apr-20-23 10:07AM
Apr-18-23 05:30AM
08:30AM Loading…
Apr-16-23 08:30AM
Apr-15-23 10:15AM
Apr-14-23 07:00AM
Apr-13-23 07:00AM
Apr-12-23 08:35AM
Apr-08-23 05:52AM
Apr-05-23 09:45AM
Apr-04-23 03:53PM
Apr-01-23 06:14AM
Mar-31-23 10:00AM
Mar-29-23 10:23PM
Mar-25-23 06:00AM
Mar-21-23 09:53AM
Mar-17-23 05:55AM
Mar-12-23 04:45PM
Mar-11-23 03:27AM
Mar-06-23 06:15AM
Mar-03-23 06:30AM
Mar-01-23 07:00AM
Feb-28-23 02:20PM
Feb-27-23 07:00AM
Feb-22-23 07:00AM
Feb-15-23 01:26PM
Feb-13-23 08:01AM
Feb-12-23 09:00AM
Feb-11-23 02:31PM
Feb-10-23 05:52AM
Feb-07-23 07:00AM
Jan-31-23 07:00AM
Jan-29-23 07:25AM
Jan-23-23 05:30AM
Jan-19-23 05:30AM
Jan-07-23 10:07AM
Dec-30-22 09:45AM
Dec-25-22 08:30AM
Dec-22-22 08:15AM
Dec-21-22 09:35AM
Dec-18-22 06:21PM
Dec-16-22 06:15AM
Dec-13-22 06:00AM
Dec-11-22 05:52AM
Dec-10-22 06:10AM
Dec-08-22 06:30AM
Dec-07-22 11:30AM
Dec-02-22 10:15AM
Nov-29-22 12:57PM
Nov-28-22 04:04PM
Nov-24-22 09:45AM
Nov-23-22 07:00AM
Nov-20-22 06:30AM
Nov-18-22 05:52AM
Nov-11-22 10:07AM
Nov-10-22 05:10AM
Nov-09-22 07:00AM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coleman MarkDirectorJan 03Option Exercise1.3017,50122,75125,097Jan 04 04:11 PM